Tuesday, March 10, 2020 Daily Archives

MilliporeSigma: Thermo Fisher’s Qiagen buy ‘no threat’ to bioprocess landscape

by

Merck KGaA says bioprocess M&A is significantly different than in the pharma world and sees no challenge to its MilliporeSigma division from Thermo Fisher’s recent acquisitions. Last week, bioprocess vendor Thermo Fisher agreed to buy Qiagen for $11.5 billion (€10.1 billion). The deal will bolster Thermo Fisher’s diagnostics business and add sample preparation, assay development and bioinformatics capabilities to its genetic analysis and biosciences capabilities. It is also the latest billion-dollar plus deal for Thermo Fisher, which has in recent…

March 10, 2020

Lonza looks to Cocoon to drive autologous cell therapy paradigm shift

by

Lonza has partnered with several academic clinical centers to assess the manufacture of cell therapies in a decentralized setting using its automated Cocoon point-of-care (PoC) platform. Swiss contract development and manufacturing organization (CDMO) Lonza announced independent research collaborations with Stanford University School of Medicine, Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy. The collaborations will see the tech transfer of cell therapy manufacturing processes developed at the respective research institutes into the Cocoon platform. The Cocoon system…

March 10, 2020